Clinical trials: Hepatobiliary Disorders
Nonalcoholic Fatty Liver Disease
Prospective Cohort, With Biobanking, of Patients With Nonalcoholic Fatty Liver Disease
The aim of the present prospective NAFLD cohort study (with biobank), of obese subjects with proven NAFLD based on liver biopsy and/or MRI, is to study factors contributing to the development of NASH in patients with simple…
- Trial name
- NAFLD-cohort (NCT02422238)
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- Maastricht University Medical Center
Pediatric Non-alcoholic Fatty Liver Disease
Comparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease worldwide, paralleling the obesity pandemic.
- Trial name
- NCT05309863
- Testing
- Lifestyle management
- Where
- 3 sites in Belgium
- Volunteers
- 850 people
- Sponsor
- University Hospital, Ghent
NASH With Fibrosis, NAFLD
AGED Diagnostics Liver Disease Assessment
Continue development of previously established methods to further validate candidate biomarkers that can discriminate steatosis from NASH and separately stage fibrosis from blood.
- Conditions
- NASH With Fibrosis, NAFLD, Healthy
- Trial name
- AGEDDX (NCT06348563)
- Testing
- AGED Multiple Target Assay in Healthy Controls, AGED Multiple Target Assay in NAFLD Participants, AGED Multiple Target Assay in Fibrosis Participants
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Active Genomes Expressed Diagnostics, Corp
Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
This study is for adults aged 18 years and older who have a type of fatty liver disease called metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- NCT07850063
- Testing
- Survodutide
- Where
- 34 sites in United States, China and 3 more
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
End Stage Liver DIsease, Liver Transplant; Complications
Association Between the Use of Pulmonary Artery Catheter and Clinical Outcomes After Liver Transplantation
The investigators attempted to evaluate whether the use of PAC is associated with better clinical outcomes after liver transplantation compared with the case without PAC.
- Conditions
- End Stage Liver DIsease, Liver Transplant; Complications, Liver Cirrhosis, Liver Diseases
- Trial name
- NCT05457114
- Testing
- Pulmonary artery catheter (Edward Lifesciences, Irvine, California, USA), FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA)
- Where
- South Korea
- Volunteers
- 1,970 people
- Sponsor
- Seoul National University Hospital
Nonalcoholic Fatty Liver Disease
Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US
Saroglitazar Magnesium 4 mg for NAFLD in People Living with HIV in the US
- Trial name
- SARONAPLUS (NCT05211284)
- Testing
- Saroglitazar Magnesium 4 mg
- Where
- 8 sites in United States
- Volunteers
- 4 people
- Sponsor
- Zydus Therapeutics Inc.
Liver Cirrhosis
Study in Patients With Decompensated Liver Cirrhosis
OPAL is a multicenter observational study, following the natural disease trajectory of participants who have permanent damage to their liver caused by scarring, sometimes also referred to as liver cirrhosis.
- Trial name
- OPAL (NCT06380335)
- Where
- 12 sites in Spain, United Kingdom
- Volunteers
- 24 people
- Sponsor
- Resolution Therapeutics Limited
Non-alcoholic Fatty Liver Disease (NAFLD)
Validation Study of the Velacur System in Comparison to MRE & MRI-PDFF in Patients With (Suspected) Liver Disease
The goal of this open-label, non-randomized, prospective study is to compare Velacur and MRE in all sexes, 18-80 years old with Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT05908006
- Testing
- Velacur
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- GI Alliance
End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis
Tocotrienol Against the Progression of End Stage Liver Disease
The purpose of this Phase 2 trial is to validate the outcome observed in a previous trial that oral Tocotrienol (TCT) attenuates the rise in MELD score over time in patients with end stage liver disease / cirrhosis.
- Conditions
- End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
- Trial name
- NCT02581085
- Testing
- Tocotrienol (TCT)
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Chandan Sen
Obesity, Diabetes Mellitus, Type 2
Bariatric Surgery-Induced Shift in Gut Microbiome and NAFLD
This study is designed as a prospective pilot study for longitudinal assessment of fecal microbiome related to medical and surgical weight loss.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, NAFLD
- Trial name
- NCT04263376
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- The Cleveland Clinic
Liver Disease Parenchymal
Bloody or Well Done. How Would You Like Your Liver Biopsy, Sir?
This is a randomized comparative trial between percutaneous liver biopsy and EUS FNB guided liver biopsy in patients with parenchymal liver disease.
- Trial name
- LIMPID (NCT06231082)
- Testing
- Group one - percutaneous (P), Group two - EUS FNB (E)
- Where
- Romania
- Volunteers
- 78 people
- Sponsor
- Carol Davila University of Medicine and Pharmacy
Nonalcoholic Fatty Liver Disease, Physician
Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease
This trial studies patient and physician perspectives on non-alcoholic fatty liver disease. Using questionnaires and interviews, this trial may help researchers understand physicians' knowledge about the diagnosis, prognosis…
- Trial name
- NCT04132440
- Testing
- Interview, Questionnaire Administration
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Inflammation, Fibrosis
Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
No proven treatment exists for nonalcoholic fatty liver disease (NAFLD) in children and adolescents. We aim to determine the efficacy of lifestyle intervention with or without antioxidant therapy in pediatric NAFLD.
- Conditions
- Inflammation, Fibrosis, Insulin Resistance
- Trial name
- VITENAFLD (NCT00655018)
- Testing
- Vitamin treatment (alpha tocopherol plus ascorbic acid)
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Nonalcoholic Fatty Liver Disease
Effectiveness of Exercise Applications on Hepatic Steatosis and Physical Fitness in Patients With NAFLD
Purpose of the study will investigate the effects of two different training programs on hepatic steatosis and physical fitness parameters.
- Trial name
- NCT03461562
- Testing
- Aerobic Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people
- Sponsor
- Okan University
Liver Neoplasms, Hepatobiliary Diseases
Outcomes After Liver and Biliary Resection at a High-Volume Center
The goal of this observational study is to evaluate clinical and oncologic outcomes in adult patients undergoing liver and/or biliary resection for benign and malignant diseases.
- Conditions
- Liver Neoplasms, Hepatobiliary Diseases, Cholangiocarcinoma, Hepatocellular Carcinoma
- Trial name
- BILIVER (NCT07556835)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Azienda USL Toscana Centro
To Evaluate the Clinical Efficacy and Safety of the New ALSS
Clinical Observation of CABA System in the Treatment of End-stage Liver Disease With Inflammation
End-stage liver disease (ESLD) refers to the late stage of liver disease caused by various chronic liver damage. ESLD is an important cause of global incidence rate and mortality, which has a significant impact on the health care…
- Trial name
- NCT05780190
- Testing
- New artificial liver CABA system (BS330+CA280) +PE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Qin Ning
Non-alcoholic Fatty Liver Disease
Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease
The purpose of this study is to evaluate the use of phlebotomy (blood taking)as a treatment for patients with non-alcoholic fatty liver disease.
- Trial name
- NCT00641524
- Testing
- Phlebotomy
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- University of Western Ontario, Canada
Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease
The purpose of this research study is to find out about the usefulness of mindfulness for weight loss and improvement of physical and mental health in people who have non-alcoholic fatty liver disease (NAFLD).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, Obesity
- Trial name
- NCT05130346
- Testing
- Mindfulness Based Stress Reduction (MBSR)
- Where
- United States
- Sponsor
- Virginia Commonwealth University
Obesity, Diabetes Mellitus
Characterization of the Microbiome in Peritoneum, Jejunum, Rectum and Stool
Characterization of the human microbiome in the jejunum and comparison to the microbiome in the rectum and stool in order to see how the microbial communities change within the intestines.
- Conditions
- Obesity, Diabetes Mellitus, Fatty Liver, Nonalcoholic, Leaky Gut Syndrome
- Trial name
- METABIOM (NCT04067440)
- Testing
- Microbial Swab
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Universität des Saarlandes
NAFLD, Non-alcoholic Fatty Liver Disease
Manual Therapy in Metabolic Liver Disease
Hepatic steatosis is a disease that is becoming more common in our society; approximately 40% of the population suffers from non-alcoholic fatty liver.
- Trial name
- OSTEO-EHMet (NCT06338618)
- Testing
- liver treatment protocol
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- University of Seville
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.